NCT01129310View on ClinicalTrials.gov

First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

May 18, 2018

Study Completion Date

May 18, 2018

Conditions
Gastrointestinal NeoplasmGastric Adenocarcinoma
Interventions
DRUG

Irinotecan-Capecitabine-Oxaliplatin

Irinotecan-160mg/m2 IV infusion over 60-90 min on Day 1 Capecitabine-1900mg/m2 daily PO in divided doses (=950mg/m2 BID) on days 2-15 Oxaliplatin- 100mg/m2 IV infusion over 2 hours Day 1

Trial Locations (1)

T6G 1Z2

Cross Cancer Institute, Edmonton

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

AHS Cancer Control Alberta

OTHER